Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3

2(66.7%)

Phase 4

1(33.3%)

3Total

Phase 3(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01281735Recruiting

International Chronic Myeloid Leukemia Pediatric Study

Role: collaborator

NCT04037189Unknown

Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia

Role: collaborator

NCT04055558Unknown

Lymphoproliferative Disorders After Diagnosis of Childhood Acute Lymphoblastic Leukemia/Lymphoma

Role: collaborator

NCT01423747Phase 3Unknown

Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia

Role: collaborator

NCT00186966Phase 3Completed

Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia

Role: collaborator

NCT00411541Phase 4Completed

Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia

Role: lead

All 6 trials loaded